III.L 0MSFT 0.31GO.U.TO 0.3CIU.PR.A.TO 0DAL -0.02CDZ.TO 0.42NET -0.42KLAC 1.81
Sarepta Therapeutics (SRPT)

NASDAQ:SRPT

Sarepta Therapeutics (SRPT)

19.25
-0.03 (0.16%)
as of Jul 2, 2026, 10:56:31 pm Market Open.
0 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
DON'T BUY

Sarepta Therapeutics(SRPT)

Jan 15, 2025

The RNA-based therapeutic companies are not doing well. Maybe it's a reverse-halo effect of the Moderna report. It's troubling.

Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$119.43

Stock price when the opinion was issued

$19.25

As of Jul 02, 2026. Market Open.

biotechnologypharmaceutical
Showing 1 to 1 of 1 entries
  • «
  • ‹
  • 1
  • ›
  • »

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

NFLX 0$77.65
GOOG -0.5$355.68
CAT 1.47$965
NFLX 0$77.65
AAPL -0.2$308.43
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

III.L 0$2999
MSFT 0.31$390.8
GO.U.TO 0.3$9.55
CIU.PR.A… 0$
DAL -0.02$92.73

Popular Articles

Latest Sell Signals

CAT 1.47$965
ASML 5.87$1775.1899
TRI.TO -1.74$124.88
EIF.TO 2.09$132.94
MU 0.84$976.4

Most Recent Experts

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Capital Area Planning Group

Kevin Simpson

Kevin Simpson

Capital Wealth Planning

Josh Brown, CEO, Ritholtz Wealth Management

Josh Brown, CEO, Ritholtz Wealth Management

Ritholtz Wealth Management

Michael Hakes - CFA, MBA

Michael Hakes - CFA, MBA

Murray Wealth Group

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

Sarepta Therapeutics (SRPT) Frequently Asked Questions

What is Sarepta Therapeutics stock symbol?

Sarepta Therapeutics is a American stock, trading under the symbol SRPT (previously SRPT-Q on Stockchase) on the NASDAQ (SRPT). It is usually referred to as NASDAQ:SRPT or SRPT

Is Sarepta Therapeutics a buy or a sell?

In the last year, no analyst issued a Buy, Sell, or Hold rating on SRPT (previously SRPT-Q on Stockchase) on Stockchase. Read the latest expert commentary for Sarepta Therapeutics.

Is Sarepta Therapeutics a good investment or a top pick?

Sarepta Therapeutics was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Sarepta Therapeutics.

Why is Sarepta Therapeutics stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Sarepta Therapeutics.

Is Sarepta Therapeutics worth watching?

Sarepta Therapeutics is covered by Stockchase experts and is worth watching.

What is Sarepta Therapeutics stock price?

On 2026-07-02, Sarepta Therapeutics (SRPT) stock closed at a price of $19.25.